Decision Resources Says by 2013 Invega Sustenna Will Be the Proprietary Clinical Gold Standard for Schizophrenia Treatment

OPEN MINDS Weekly News Wire Mental Health & Chemical Dependency Services After reviewing current and emerging long-acting injectable antipsychotic medications, Decision Resources said Invega Sustenna (paliperidone palmitate), an atypical antipsychotic administered in a monthly injection, will become its proprietary clinical gold standard for schizophrenia treatment in 2013. The Invega Sustenna long-acting injection was selected because the dosing schedule greatly improves patients’ ability to comply with treatment. The selection bumped a Risperdal Consta (risperidone) injection with a two-week duration from the gold standard slot. The selection was noted in a report, “Schizophrenia: Emerging Atypical Depot Formulations Must Meet . . .